Skip to content

Author

D. Herrmann

We have 2 of 92 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Sep 2026

Abstract A035: Co-targeting emergent vulnerabilities to overcome FOLFIRINOX resistance in pancreatic cancer

Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy, with a five-year survival rate of just 13%. For the >80% of patients presenting with metastatic disease, standard-of-care systemic chemotherapies such as FOLFIRINOX or gemcitabine/nab-paclitaxel (GnP) inevitably induce resistance, frequently forci...

Brooke A. Pereira, Katie A. Gordon, Victoria M. Tyma et al. · 0 citations
Sep 2026

Abstract A056: Targeting the mutant p53 cancer cell secretome sensitizes tumors to gemcitabine/nab-paclitaxel chemotherapy and reduces metastasis in pancreatic cancer

Pancreatic ductal adenocarcinoma (PDAC) remains a highly lethal and metastatic malignancy, with standard-of-care treatments, such as gemcitabine/nab-paclitaxel (GnP) offering limited improvement for patients with advanced disease. We and others have shown that co-targeting key factors in combination with chemotherapy...

Shona Ritchie, Victoria M. Tyma, Shanna Hafiz et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.